Replies to post #420779 on Amarin Corp Plc (AMRN)

[couldbebetter]

AMRN is already deciding how to price Vascepa everywhere but China.
What I think BP will do is determine how they would price Vascepa if they
owned AMRN and figure out what the return would be under their own
distribution network. If the supply available for Europe (or at least where
reimbursements are approved) is limited, BP would only sell it where it
makes economic sense to do so Should those projected peak sales for Europe
come out to $1.5 billion, the BO value could be around $6.75 billion which would
be around $16 a share. Will the US, China, & ROW have significant value under
BP ownership? Hopefully it would. Getting the CVD indication for China could be
interesting. The BP acquirer would want to create an aura around Vascepa that
it is a high quality, safe, effective, & cost effective medication. Differentiating Vascepa
from all other Omega-3 products (including prescription and supplements) is VITAL!